Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Olga Bandman, MD
ARYx Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
40 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Aryx Investigational Site
Edmonton, Alberta, Canada
- Aryx Investigational Site
Edmonton, Alberta, Canada
- Aryx Investigational Site
Campbell River, British Columbia, Canada
- Aryx Investigational Site
Vancouver, British Columbia, Canada
- Aryx Investigational Site
Victoria, British Columbia, Canada
- Aryx Investigational Site
London, Ontario, Canada
- Aryx Investigational Site
Niagara Falls, Ontario, Canada
- Aryx Investigational Site
Ottawa, Ontario, Canada
- Aryx Investigational Site
Montreal, Quebec, Canada
- Aryx Investigational Site
Montreal, Quebec, Canada
- Aryx Investigational Sites
Montreal, Quebec, Canada
- Aryx Investigational Site
Sherbrooke, Quebec, Canada
- Aryx Investigational Site
Terrebonne, Quebec, Canada
- Aryx Investigational Site
Phoenix, Arizona, United States
- Aryx Investigational Site
Scottsdale, Arizona, United States
- Aryx Investigational Site
Tucson, Arizona, United States
- Aryx Investigational Site
Larkspur, California, United States
- Aryx Investigational Site
Aurora, Colorado, United States
- Aryx Investigational Site
Hollywood, Florida, United States
- Aryx Investigational Site
Jacksonville Beach, Florida, United States
- Aryx Investigational Site
Atlanta, Georgia, United States
- Aryx Investigational Site
Marietta, Georgia, United States
- Aryx Investigational Site
Chicago, Illinois, United States
- Aryx Investigational Site
Towson, Maryland, United States
- Aryx Investigational Site
Saginaw, Michigan, United States
- Aryx Investigational Site
Minneapolis, Minnesota, United States
- Aryx Investigational Site
St Louis, Missouri, United States
- Aryx Investigational Site
Lincoln, Nebraska, United States
- Aryx Investigational Site
Warren Township, New Jersey, United States
- Aryx Investigational Site
Albuquerque, New Mexico, United States
- Aryx Investigational Site
Buffalo, New York, United States
- Aryx Investigational Site
Hershey, Pennsylvania, United States
- Aryx Investigational Site
Wynnewood, Pennsylvania, United States
- Aryx Investigational Site
Charleston, South Carolina, United States
- Aryx Investigational Site
Nashville, Tennessee, United States
- Aryx Investigational Site
Austin, Texas, United States
- Aryx Investigational Site
Houston, Texas, United States
- Aryx Investigational Site
Burlington, Vermont, United States
- Aryx Investigational Site
Newport News, Virginia, United States
- Aryx Investigational Site
Charleston, West Virginia, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2006
- Primary completion
- 31 Dec 2008
- Completion
- 31 Dec 2008
- Last update posted
- 11 Mar 2009
- Registered enrollment
- 72
- Registry id
- NCT00389792
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.